KIR2DL1 and leukemia: Bari and colleagues showed that patients who received a KIR2DL1-R(245)-positive graft with HLA-C receptor–ligand mismatch had the best survival and lowest risk of leukemia progression compared with those patients who received a KIR2DL1-C(245) homozygous graft [19].